The short fiber knobs of human adenovirus in species F elicit cross-neutralizing antibody responses

被引:1
|
作者
Liu, Zhenwei [1 ,2 ,3 ]
Tang, Guolu [1 ,2 ]
Peng, Yinghui [1 ,2 ]
Lan, Jixian [4 ]
Xian, Yuting [4 ]
Tian, Xingui [3 ]
Chen, Dehui [1 ]
机构
[1] Guangzhou Med Univ, Affiliated Hosp 1, Dept Pediat, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, State Key Lab Resp Dis, Guangdong Hong Kong Macao Joint Lab Resp Infect Di, Guangzhou, Peoples R China
[3] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China
[4] Guangdong Sanmai Biotechnol Co Ltd, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Human adenovirus type 40 and 41; Short fiber knob; Cross-neutralization; MOLECULAR CHARACTERIZATION; ACUTE GASTROENTERITIS; CHILDREN; IDENTIFICATION; RECEPTOR; TRANSMISSION; DIARRHEA; VECTORS; HEXON; AGE;
D O I
10.1016/j.heliyon.2024.e35783
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Human adenovirus (HAdV) type 40 in species F (HAdV-F40) and HAdV-F41 represent the third most prevalent causative agents of non-bacterial acute gastroenteritis in infants and young children, following norovirus and rotavirus. Despite their significant contribution to global child morbidity, vaccines to preemptively combat these viruses remain elusive. In this study, we investigate the potential for cross-neutralization between HAdV-F40 and HAdV-F41 using immune sera with the short fiber knob (SFK). We implemented a series of assays to evaluate the responses, including enzyme-linked immunosorbent, micro-neutralization, immunofluorescence, and quantitative polymerase chain reaction. Our results demonstrate that immune sera with HAdV-F40 SFK or HAdV-F41 SFK could effectively neutralize both HAdV-F40 and HAdV-F41, indicating a mutual cross-neutralizing effect. Notably, the immune sera with HAdV-F40 SFK demonstrated a stronger neutralization effect, suggesting the potential to develop a subunit vaccine that can simultaneously counteract both viruses. These findings underscore the potential of SFK immunization in evoking a cross-neutralizing antibody response between HAdV-F40 and HAdV-F41. This suggests a promising avenue for developing subunit vaccines against HAdV-F40 and HAdV-F41 and provides a novel perspective on the potential of neutralizing antibodies to protect against these two types of HAdV.
引用
收藏
页数:12
相关论文
共 41 条
  • [31] Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types
    Zhang, Ting
    Liu, Hongyang
    Chen, Xue
    Wang, Zhirong
    Wang, Shuo
    Qu, Chunfeng
    Zhang, Jingzhi
    Xu, Xuemei
    VACCINE, 2016, 34 (46) : 5531 - 5539
  • [32] Enhancement of α-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro -: Implications for vaccine design
    Joyce, JG
    Hurni, WM
    Bogusky, MJ
    Garsky, VM
    Liang, XP
    Citron, MP
    Danzeisen, RC
    Miller, MD
    Shiver, JW
    Keller, PM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (48) : 45811 - 45820
  • [33] Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types
    Chen, Xue
    Liu, Hongyang
    Wang, Zhirong
    Wang, Shuo
    Zhang, Ting
    Hu, Meili
    Qiao, Liang
    Xu, Xuemei
    ONCOTARGET, 2017, 8 (38) : 63333 - 63344
  • [34] Differences between original strains and their mouse-adapted variants of human (H1) and avian (H2) influenza A viruses in the reaction with cross-neutralizing monoclonal antibody recognizing conformational epitope
    Lipatov, AS
    Gitelman, AK
    Smirnov, YA
    ACTA VIROLOGICA, 1996, 40 (04) : 227 - 230
  • [35] VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
    Kulemzin, Sergey, V
    Sergeeva, Maria, V
    Baranov, Konstantin O.
    Gorchakov, Andrey A.
    Guselnikov, Sergey, V
    Belovezhets, Tatyana N.
    Volkova, Olga Yu
    Najakshin, Alexander M.
    Chikaev, Nikolai A.
    Danilenko, Daria M.
    Taranin, Alexander, V
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (06):
  • [36] Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody
    Liu, DW
    Chang, JL
    Tsao, YP
    Huang, CW
    Kuo, SW
    Chen, SL
    INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (01) : 93 - 100
  • [37] Exploiting Natural Cross-reactivity between HIV-1 p17 Protein and 2F5 Antibody to Induce Neutralizing Responses In Vivo
    Phelip, Capucine
    Paul, Stephane
    Terrat, Celine
    Bastide, Liza
    Ensinas, Agathe
    Bulens-Grassigny, Laura
    Jospin, Fabienne
    Guillon, Christophe
    Verrier, Bernard
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 324 - 324
  • [38] Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants
    Tai, Wanbo
    Wang, Yufei
    Fett, Craig A.
    Zhao, Guangyu
    Li, Fang
    Perlman, Stanley
    Jiang, Shibo
    Zhou, Yusen
    Du, Lanying
    JOURNAL OF VIROLOGY, 2017, 91 (01)
  • [39] Enhancement of α-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro.: Implications for vaccine design (vol 277, pg 45811, 2002)
    Joyce, JG
    Hurni, WM
    Bogusky, MJ
    Garsky, VM
    Liang, XP
    Citron, MP
    Danzeisen, RC
    Miller, MD
    Shiver, JW
    Keller, PM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (07) : 5492 - 5492
  • [40] Erratum: Enhancement of α-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design (Journal of Biological Chemistry (2002) 277 (45811-45820))
    Joyce, Joseph G.
    Hurni, William M.
    Bogusky, Michael J.
    Garsky, Victor M.
    Liang, Xiaoping
    Citron, Michael P.
    Danzeisen, Renee C.
    Miller, Michael D.
    Shiver, John W.
    Keller, Paul M.
    Journal of Biological Chemistry, 2003, 278 (07)